BR112022000322A2 - Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer - Google Patents

Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer

Info

Publication number
BR112022000322A2
BR112022000322A2 BR112022000322A BR112022000322A BR112022000322A2 BR 112022000322 A2 BR112022000322 A2 BR 112022000322A2 BR 112022000322 A BR112022000322 A BR 112022000322A BR 112022000322 A BR112022000322 A BR 112022000322A BR 112022000322 A2 BR112022000322 A2 BR 112022000322A2
Authority
BR
Brazil
Prior art keywords
disease
alzheimer
biomarker
blood samples
clinically diagnosed
Prior art date
Application number
BR112022000322A
Other languages
English (en)
Inventor
Arendt Thomas
Brownell Elise
Commissiong Gerald
Trzepacz Paula
Weiss Herman
Original Assignee
Todos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Todos Medical Ltd filed Critical Todos Medical Ltd
Publication of BR112022000322A2 publication Critical patent/BR112022000322A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer. a presente invenção divulga um método para diagnosticar doença de alzheimer com o uso de biomarcadores, e análise multivariada que fornece um método de detecção minimamente ou não invasivo mais confiável. a invenção divulga a detecção simultânea de proteínas cd69 em linfócitos mitogênicos, proteínas tau e tau fosforiladas, e peptídeos ß-amiloides em líquido cefalorraquidiano, o que pode substituir ou suplementar os métodos convencionais de detecção de doença de alzheimer tais como testes cognitivos e tomografia por emissão de pósitrons de amiloide.
BR112022000322A 2019-07-10 2020-07-10 Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer BR112022000322A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872567P 2019-07-10 2019-07-10
PCT/IB2020/056509 WO2021005568A1 (en) 2019-07-10 2020-07-10 A biomarker for alzheimer's disease using blood samples from clinically diagnosed alzheimer's disease subjects

Publications (1)

Publication Number Publication Date
BR112022000322A2 true BR112022000322A2 (pt) 2022-02-22

Family

ID=74114470

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000322A BR112022000322A2 (pt) 2019-07-10 2020-07-10 Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer

Country Status (9)

Country Link
US (1) US20220260595A1 (pt)
JP (1) JP2022545153A (pt)
KR (1) KR20220034769A (pt)
CN (1) CN114174830A (pt)
BR (1) BR112022000322A2 (pt)
CA (1) CA3144876A1 (pt)
MX (1) MX2022000444A (pt)
WO (1) WO2021005568A1 (pt)
ZA (1) ZA202201448B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11621087B2 (en) * 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
CN117210549A (zh) * 2023-08-29 2023-12-12 河络新图生物科技(上海)有限公司 检测人atp5d、cd69和cxcr4基因的物质及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10349162A1 (de) * 2003-10-22 2005-06-02 Universität Leipzig Schnelltest zur Diagnose der Alzheimerschen Erkrankung
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
US20130273574A1 (en) * 2012-03-13 2013-10-17 Janssen Alzheimer Immunotherapy Oligomeric a-beta in the diagnosis, prognosis, and monitoring of alzheimer's disease

Also Published As

Publication number Publication date
ZA202201448B (en) 2022-09-28
US20220260595A1 (en) 2022-08-18
KR20220034769A (ko) 2022-03-18
JP2022545153A (ja) 2022-10-26
MX2022000444A (es) 2022-02-10
CN114174830A (zh) 2022-03-11
CA3144876A1 (en) 2021-01-14
WO2021005568A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
Lleó et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
Toledo et al. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease
Ashton et al. No association of salivary total tau concentration with Alzheimer's disease
Lagerstedt et al. H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury
Schilde et al. Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research
EP3260866B1 (en) Novel biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers
German et al. Serum biomarkers for Alzheimer's disease: proteomic discovery
Alcolea et al. Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias
Marksteiner et al. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study
BR112022000322A2 (pt) Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer
DK3171174T3 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease
Bellomo et al. Machine learning driven profiling of cerebrospinal fluid core biomarkers in Alzheimer’s disease and other neurological disorders
EP3088899B1 (en) Biomarkers for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
Ye et al. Dementia-predicting cognitive risk score and its correlation with cortical thickness in Parkinson disease
JP6839854B2 (ja) 星状細胞トラウマトーム（ｔｒａｕｍａｔｏｍｅ）および神経外傷のバイオマーカー
Yang et al. An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression
JP6262727B2 (ja) アルツハイマー病及び軽度認知障害関連トロポミオシンアイソフォーム
Gamir-Morralla et al. Kidins220 correlates with Tau in alzheimer’s disease brain and cerebrospinal fluid
Zondra Revendova et al. Demographic and disease‐related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis
Urso et al. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease
Maple-Grødem et al. Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach
EP3149473A2 (en) Metabolic biomarkers for memory loss
US10502749B1 (en) Method for patient stratification and drug efficacy monitoring
Lewis Please let us know how this document benefits you.
Fang Changes of serum cortisol and IL-6 levels before and after exercise stress test and their relationship with white coat hypertension

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]